Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158175 | 0.82 | CXCL8 (0.54) | MEN1KMT2AROCK2CYP1A2HPGD | |
| SCHEMBL29620332 | 0.82 | MEN1 (0.50) | MEN1KMT2AROCK2ALDH1A1CYP1A2 | |
| SCHEMBL29512015 | 0.82 | CXCL8 (0.54) | MEN1KMT2AROCK2CYP1A2HPGD | |
| SCHEMBL19808776 | 0.81 | MEN1 (0.50) | MEN1KMT2AALDH1A1CYP1A2HPGD | |
| SCHEMBL1417236 | 0.81 | POLB (0.48) | MEN1KMT2AROCK2ALDH1A1CYP1A2 | |
| SCHEMBL19808778 | 0.81 | HTT (0.46) | MEN1KMT2AROCK2ALDH1A1CYP1A2 | |
| SCHEMBL29512022 | 0.81 | POLB (0.48) | MEN1KMT2AROCK2ALDH1A1CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL23300490 | 0.81 | CXCL8 (0.53) | MEN1KMT2AROCK2CYP1A2HPGD | |
| SCHEMBL6314444 | 0.81 | CYP1A2 (0.51) | MEN1KMT2AROCK2ALDH1A1CYP1A2 | |
| SCHEMBL28306745 | 0.81 | CXCL8 (0.53) | MEN1KMT2AROCK2CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875626-B2 | 3,3,3-trifluoropropane-1-sulfonic acid 4-[1-(2-chlorophenyl)-3-methyl-4-oxo-5-piperidin-1-yl-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridine-2-yl]phenyl ester; treatment of obesity, psychiatric and neurological disorders | ASTRAZENECA AB (SE) | 2011-01-25 | — | — | US | disclosed |
| WO-2009147170-A2 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-10 | — | — | WO | disclosed |
| EP-1937679-B1 | PREPARATION AND USE OF TETRAHYDROPYRROLO [3, 2-C] PYRIDIN-4-ONE DERIVATIVES FOR TREATMENT OF OBESITY, PSYCHIATRIC AND NEUROLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | EP | disclosed |
| US-7576095-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-08-18 | — | — | US | disclosed |
| US-20080312269-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1937679-A2 | PREPARATION AND USE OF TETRAHYDROPYRROLO [3, 2-C] PYRIDIN-4-ONE DERIVATIVES FOR TREATMENT OF OBESITY, PSYCHIATRIC AND NEUROLOGICAL DISORDERS | AstraZeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| US-20080009513-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| WO-2007039740-A2 | PREPARATION AND USE OF TETRAHYDROPYRROLO [3, 2-C] PYRIDIN-4-ONE DERIVATIVES FOR TREATMENT OF OBESITY, PSYCHIATRIC AND NEUROLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| US-7071207-B2 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060122215-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | US | disclosed |
| EP-1432708-B1 | PREPARATION AND USE OF 1,5,6,7-TETRAHYDROPYRROLO 3,2-C]PYRIDINE DERIVATIVES FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORP (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20040224970-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009513-A1 | Therapeutic agents | NLN, GPR119, FABP4 | MEN1 3167/4885KMT2A 3490/4885ROCK2 3788/4885 |
| US-20040224970-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity | GPR119, GIPR, PGC | MEN1 3413/4885KMT2A 1681/4885ROCK2 1846/4885 |
| US-20080312269-A1 | Therapeutic Agents | NLN, GRIN2C, GPR119 | MEN1 3251/4885KMT2A 3667/4885ROCK2 3580/4885 |
| US-20060122215-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity | GPR119, GIPR, PGC | MEN1 2207/4885KMT2A 1796/4885ROCK2 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.